The U.S. Court of Appeals for the Fifth Circuit ruled on August 27, 2026, upholding the FDA’s determination that semaglutide and tirzepatide are no longer in shortage. The decision eliminates the legal basis for pharmacies and outsourcing facilities to mass-produce copycat versions of the approved GLP-1 drugs. A companion opinion in the tirzepatide case reached the same result the same day.
The ruling locks in supply restrictions that have been tightening since enforcement discretion ended for 503B outsourcing facilities in March 2025 and for 503A pharmacies in May 2025. A federal court previously upheld the agency’s position in May 2025, and the Fifth Circuit has now affirmed that outcome at the appellate level.
For patients who have relied on compounded versions of these medications, the decision signals a further contraction of access. Telehealth platforms that once sourced from dozens of compounding suppliers are consolidating toward a smaller pool of five to ten 503B outsourcing facilities.
What happened
Under federal compounding law, a drug’s shortage designation allows 503A compounding pharmacies and 503B outsourcing facilities to produce compounded versions of that drug. Once the FDA determines a shortage is resolved, that legal basis is removed.
The FDA determined that semaglutide and tirzepatide — the active ingredients in widely prescribed GLP-1 receptor agonist medications — were no longer in shortage. Enforcement discretion for 503B outsourcing facilities ended in March 2025, followed by 503A pharmacies in May 2025. A federal court upheld the agency’s position in May 2025.
The Fifth Circuit’s August 27, 2026 ruling affirmed that decision. A companion opinion addressing tirzepatide reached the same conclusion on the same day, closing the legal avenue for mass compounding of both drugs at the appellate level.
Why it matters
The decision reshapes the GLP-1 supply chain. Compounding pharmacies that produced copycat versions of semaglutide or tirzepatide no longer have a legal basis for mass production. Telehealth platforms that prescribed compounded GLP-1 medications are seeing their supplier networks shrink from dozens of compounding pharmacies to an estimated five to ten 503B outsourcing facilities.
Patients who depended on compounded versions of these drugs face reduced access. The ruling narrows the market to FDA-approved products and a limited number of outsourcing facilities that may still operate within regulatory boundaries.
What to watch next
- How telehealth platforms adjust prescribing and sourcing models in response to the consolidated supplier landscape
- Whether compounding pharmacies or outsourcing facilities pursue further legal challenges
- How state pharmacy boards respond to the tightened enforcement environment
- Whether patient access concerns prompt any legislative or regulatory responses
Sources
Industry information only. Not medical or legal advice.
